A Study of LY03005 vs Pristiq

NCT ID: NCT03733574

Last Updated: 2018-11-09

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 56 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-06-19
• Study Completion Date: 2018-07-26

Brief Summary

The objective of this study is to evaluate relative bioavailability between 80 mg LY03005 oral tablets and 50 mg Pristiq® oral tablets after a single dose of each drug in a cross-over 2-period design under fasting condition in healthy subjects between 18 and 50 years of age.

Detailed Description

Fifty six (56) eligible subjects will be enrolled and assigned to either Group A or Group B at a 1:1 ratio.

Conditions

Major Depressive Disorder

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

LY03005 cross-over to Pristiq® (Desvenlafaxine)

Subjects in this group will receive an 80 mg oral dose of LY03005. After a washout period of up to 4 days, the subjects will be switched and will receive a 50 mg oral dose of desvenlafaxine (Pristiq®).

Group Type: EXPERIMENTAL

LY03005

Intervention Type: DRUG

Drug: LY03005 80 mg, oral tablets, single dose

Pristiq

Intervention Type: DRUG

Drug: Pristiq 50 mg, oral tablets, single dose

Pristiq® (Desvenlafaxine) cross-over to LY03005

Subjects in this group will receive a 50 mg oral dose of desvenlafaxine (Pristiq®) After a washout period of up to 4 days, the subjects will be switched and will receive an 80 mg oral dose of LY03005

Group Type: EXPERIMENTAL

LY03005

Intervention Type: DRUG

Drug: LY03005 80 mg, oral tablets, single dose

Pristiq

Intervention Type: DRUG

Drug: Pristiq 50 mg, oral tablets, single dose

Interventions

LY03005

Drug: LY03005 80 mg, oral tablets, single dose

Intervention Type: DRUG

Pristiq

Drug: Pristiq 50 mg, oral tablets, single dose

Intervention Type: DRUG

Other Intervention Names

Desvenlafaxine

Eligibility Criteria

Inclusion Criteria

1. Capable of giving informed consent and complying with trial procedures;

2. Male and female subjects between the ages of 18 and 50 years, inclusive;

3. Considered healthy by the Investigator based on a detailed medical history, full physical examination, clinical laboratory tests, 12-lead ECG, and vital signs;

4. Nonsmoker, defined as not having smoked or used any form of tobacco for at least 6 months before Screening based on subject report;

5. Body mass index (BMI) of 19 to 30 kg/m2 inclusive and body weight not less than 50 kg;

6. Willing and able to adhere to trial procedures and to be confined at the clinical research unit (CRU).

7. All female subjects (childbearing potential and non-childbearing potential) must have a negative serum pregnancy test result at Screening. In addition, female subjects must meet 1 of the following 3 conditions: (i) postmenopausal for at least 12 months without an alternative medical cause, (ii) surgically sterile (hysterectomy, bilateral oophorectomy, bilateral salpingectomy, or bilateral tubal occlusion) based on subject report, or (iii) if of childbearing potential and heterosexually active, practicing or agree to practice a highly effective method of contraception. Highly effective methods of birth control include an intrauterine device (IUD), intrauterine hormone-releasing system (IUS), and contraceptives (oral, skin patches, or implanted or injectable products) using combined or progestogen-only hormonal contraception associated with inhibition of ovulation. A vasectomized male partner is an acceptable birth control method if the vasectomized partner is the sole sexual partner of the female subject and the vasectomized partner has received medical confirmation of surgical success.

Highly effective methods of birth control must be used for at least 14 days prior to study drug dosing, through the end of study (EOS) visit or early termination, and for a minimum of 1 month after the last dose of study drug to minimize the risk of pregnancy. Sexually active, fertile, male subjects must be willing to use acceptable contraception methods (such as double-barrier methods of a combination of male condom with either cap, diaphragm, or sponge with spermicide) from the first dose of study drug through the EOS visit or early termination, and for a minimum of 1 month after the last dose of study drug.

Exclusion Criteria

1. Clinically significant past medical history of gastrointestinal, cardiovascular, musculoskeletal, endocrine, hematologic, psychiatric (including life-long history of depression and/or anxiety), renal, hepatic, bronchopulmonary, neurologic, immunologic, ophthalmological, or lipid metabolism disorders; or drug hypersensitivity; or any other condition that in the judgement of the Investigator will affect the trial results or the subject's safety;

2. History of suicide attempt in the past 12 months and/or seen by the Investigator as having a significant history of risk of suicide or homicide;

3. History or presence of malignancy other than adequately treated and cured basal cell carcinoma or squamous cell carcinoma (skin cancer);

4. Clinically relevant illness within 1 month prior to Screening or at Screening that may interfere with the conduct of this trial;

5. Medically uncontrolled high blood pressure with mean systolic blood pressure >140 mmHg or mean diastolic blood pressure >90 mmHg at Screening after 3 measurements (after at least 5 minutes of rest in a seated position);

6. History of Long QT Syndrome (LQTS) or a marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval >450 ms);

7. Positive blood screen for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C antibody;

8. History of seizure (history of febrile seizure allowed);

9. Hospital admission or major surgery within 30 days prior to Screening;

10. Participation in any other investigational drug trial within 30 days prior to Screening;

11. History of prescription drug abuse or illicit drug use within 6 months prior to Screening;

12. History of alcohol abuse according to medical history within 6 months prior to Screening;

13. Positive screen for alcohol and/or drugs of abuse;

14. Tobacco use within 6 months prior to Screening based on positive nicotine screen;

15. History of intolerance or hypersensitivity to ODV or medicines containing ODV or its precursor venlafaxine;

16. Participation in a previous clinical trial of either LY03005 or ODV or medicines containing ODV or its precursor, venlafaxine, within 30 days prior to Screening;

17. Unwillingness or inability to comply with food and beverage restrictions during trial participation;

18. Donation of blood of more than 1 unit (approximate 450 mL) or blood products or acute loss of blood during the 90 days prior to Screening;

19. Use of prescription or over-the-counter (OTC) medications and/or herbals (including St John's Wort, herbal teas, garlic extracts) within 14 days prior to dosing (Note: Use of acetaminophen at <3g/day is permitted until 24 hours prior to dosing).

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 50 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Luye Pharma Group Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Amy Sun, MD, PhD, MBA

Role: STUDY_CHAIR

Luye Pharma Group Ltd.

Locations

Pharmaron CPC, Inc.

Baltimore, Maryland, United States

Countries

United States

Related Links

http://druginfo.nlm.nih.gov/drugportal/

Drug information

http://druginfo.nlm.nih.gov/drugportal/name/Desvenlafaxine

Desvenlafaxine

http://druginfo.nlm.nih.gov/drugportal/name/desvenlafaxine%20succinate

Desvenlafaxine Succinate

http://clinicaltrials.gov/ct2/info/fdalinks

U.S. FDA Resources

http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021992s030lbl.pdf

Pristiq (Desvenlafaxine) Label - FDA

Other Identifiers

LY03005/CT-USA-106

Identifier Type: -

Identifier Source: org_study_id